Trial Profile
Follow up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2019
Price :
$35
*
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors Astellas Institute for Regenerative Medicine
- 30 Oct 2019 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Planned End Date changed from 1 Aug 2029 to 1 Dec 2019.
- 13 Jun 2017 Planned primary completion date changed from 1 Aug 2029 to 1 Dec 2019.